Zacks Investment Research lowered shares of Trupanion (NASDAQ:TRUP) from a hold rating to a strong sell rating in a research note issued to investors on Thursday.
According to Zacks, “Trupanion, Inc. operates as a direct-to-consumer monthly subscription service provider of a medical insurance plan for cats and dogs. It operates primarily in Canada, Puerto Rico, and the United States. The Company serves pet owners and veterinarians. Trupanion, Inc. is headquartered in Seattle, Washington. “
Several other equities research analysts also recently commented on the stock. BidaskClub upgraded shares of Trupanion from a hold rating to a buy rating in a research note on Monday, December 18th. Stifel Nicolaus restated a buy rating and issued a $34.00 target price (up previously from $33.00) on shares of Trupanion in a research note on Wednesday, February 14th. Lake Street Capital boosted their target price on shares of Trupanion from $32.00 to $41.00 and gave the company a buy rating in a research note on Wednesday, February 14th. Cowen restated an outperform rating and issued a $38.00 target price (up previously from $32.00) on shares of Trupanion in a research note on Wednesday, February 14th. Finally, Northland Securities restated a buy rating and issued a $38.00 target price on shares of Trupanion in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Trupanion has a consensus rating of Buy and an average price target of $35.57.
Trupanion (NASDAQ:TRUP) last issued its earnings results on Tuesday, February 13th. The financial services provider reported ($0.05) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.03). Trupanion had a negative net margin of 0.62% and a negative return on equity of 6.66%. The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $65.60 million. sell-side analysts forecast that Trupanion will post -0.05 EPS for the current year.
In related news, insider Darryl Rawlings sold 4,000 shares of Trupanion stock in a transaction dated Tuesday, April 10th. The stock was sold at an average price of $26.72, for a total value of $106,880.00. Following the completion of the transaction, the insider now directly owns 1,367,976 shares of the company’s stock, valued at $36,552,318.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Murray B. Low sold 3,000 shares of Trupanion stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $28.42, for a total value of $85,260.00. Following the completion of the transaction, the director now directly owns 194,281 shares of the company’s stock, valued at $5,521,466.02. The disclosure for this sale can be found here. Insiders sold 25,000 shares of company stock valued at $761,745 over the last ninety days. 31.24% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in TRUP. First Mercantile Trust Co. bought a new position in shares of Trupanion in the fourth quarter valued at about $129,000. JPMorgan Chase & Co. bought a new position in shares of Trupanion in the third quarter valued at about $143,000. Advisor Group Inc. bought a new position in shares of Trupanion in the fourth quarter valued at about $182,000. Oppenheimer Asset Management Inc. bought a new position in shares of Trupanion in the third quarter valued at about $221,000. Finally, PEAK6 Investments L.P. bought a new stake in Trupanion during the 4th quarter worth about $289,000. 74.75% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/04/16/zacks-investment-research-downgrades-trupanion-trup-to-strong-sell.html.
Trupanion, Inc, together with its subsidiaries, provides medical insurance for cats and dogs on monthly subscription basis in the United States, Canada, and Puerto Rico. The company operates through Subscription Business and Other Business segments. It serves pet owners and veterinarians through third-party referrals and online member acquisition channels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.